Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F12%3A10133074" target="_blank" >RIV/00216208:11140/12:10133074 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/12:00057270 RIV/00843989:_____/12:00102834 RIV/00669806:_____/12:10133074

Výsledek na webu

<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315738/pdf/1471-2458-12-117.pdf" target="_blank" >http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315738/pdf/1471-2458-12-117.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/1471-2458-12-117" target="_blank" >10.1186/1471-2458-12-117</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry

Popis výsledku v původním jazyce

Background: Colorectal cancer (CRC) represents a serious health care problem in the Czech Republic. The prevalence of patients requiring anti-tumour therapy is also of great importance, as it is directly associated with planning of health care resources.Methods: This work proposes a population-based model for the estimation of stage-specific prevalence of CRC patients who will require active anti-tumour therapy in a given year. Its applicability is documented on records of the Czech National Cancer Registry (CNCR), which is used to estimate the number of patients potentially treated with anti-tumour therapy in the Czech Republic in 2015. Results: Based on the scenarios, the model predicts an increase in CRC prevalence from 13% to 30% in comparison withthe situation in 2008. Moreover, the model predicts that 10,074 to 11,440 CRC patients will be indicated for anti-tumour therapy in the Czech Republic in 2015. Considering all patients with terminal cancer recurrence and all patients pri

Název v anglickém jazyce

Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry

Popis výsledku anglicky

Background: Colorectal cancer (CRC) represents a serious health care problem in the Czech Republic. The prevalence of patients requiring anti-tumour therapy is also of great importance, as it is directly associated with planning of health care resources.Methods: This work proposes a population-based model for the estimation of stage-specific prevalence of CRC patients who will require active anti-tumour therapy in a given year. Its applicability is documented on records of the Czech National Cancer Registry (CNCR), which is used to estimate the number of patients potentially treated with anti-tumour therapy in the Czech Republic in 2015. Results: Based on the scenarios, the model predicts an increase in CRC prevalence from 13% to 30% in comparison withthe situation in 2008. Moreover, the model predicts that 10,074 to 11,440 CRC patients will be indicated for anti-tumour therapy in the Czech Republic in 2015. Considering all patients with terminal cancer recurrence and all patients pri

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BMC Public Health

ISSN

1471-2458

e-ISSN

—

Svazek periodika

12

Číslo periodika v rámci svazku

117

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

—

Kód UT WoS článku

000302376800001

EID výsledku v databázi Scopus

—